Covaxin 77.8% effective against Covid-19

Medical journal Lancet has now stated that the made-in-India vaccine is 77.8 per cent effective against symptomatic Covid, as demonstrated by the phase 3 data. This came out after the World Health Organisation (WHO) approved Bharat Biotech’s Covaxin for emergency use.

The efficacy data demonstrated 70.8 per cent protection against all variants of the SARS-CoV-2 virus.

As per the phase 3 data, Covaxin was found to be 65.2 per cent effective against the Delta variant, 93.4 per cent effective against severe symptomatic Covid and 63.6 per cent effective against asymptomatic Covid.

Dr. Krishna Ella, CMD of Bharat Biotech said, “The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine, validates our commitment to data transparency and meeting the stringent peer-review standards of world-leading medical journals. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, Indian Council of Medical Research, National Institute of Virology, and the trust imposed by our trial participants who made this happen.”